| __timestamp | Bristol-Myers Squibb Company | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 3932000000 | 9136000 |
| Thursday, January 1, 2015 | 3909000000 | 5807000 |
| Friday, January 1, 2016 | 4946000000 | 5571000 |
| Sunday, January 1, 2017 | 6066000000 | 5366000 |
| Monday, January 1, 2018 | 6547000000 | 6337000 |
| Tuesday, January 1, 2019 | 8078000000 | 11347000 |
| Wednesday, January 1, 2020 | 11773000000 | 30419000 |
| Friday, January 1, 2021 | 9940000000 | 62176000 |
| Saturday, January 1, 2022 | 10137000000 | 52827000 |
| Sunday, January 1, 2023 | 10693000000 | 35049000 |
| Monday, January 1, 2024 | 11949000000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. Bristol-Myers Squibb Company (BMY) and Ligand Pharmaceuticals Incorporated (LGND) offer a fascinating study in contrasts. Over the past decade, BMY has consistently managed a cost of revenue that dwarfs LGND's by a staggering ratio of approximately 300:1. This disparity highlights BMY's expansive operations and market reach compared to LGND's more niche focus.
From 2014 to 2023, BMY's cost of revenue surged by 172%, peaking in 2020 with a 200% increase from its 2014 baseline. Meanwhile, LGND's cost of revenue, though significantly smaller, saw a remarkable 283% increase, reflecting its growth trajectory. This data underscores the diverse strategies and market positions of these two industry players. As the pharmaceutical sector evolves, understanding these dynamics is crucial for investors and industry watchers alike.
AbbVie Inc. vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Amgen Inc. vs Bristol-Myers Squibb Company
Comparing Cost of Revenue Efficiency: Sanofi vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: Bristol-Myers Squibb Company vs Incyte Corporation
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Pharming Group N.V.
Bristol-Myers Squibb Company and Ligand Pharmaceuticals Incorporated: A Comprehensive Revenue Analysis
Cost Insights: Breaking Down Bristol-Myers Squibb Company and Celldex Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Incyte Corporation and Ligand Pharmaceuticals Incorporated
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Perrigo Company plc vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Galapagos NV